Less Radical, a documentary podcast that tells story of Bernie Fisher, a pioneering surgeon-scientist who redefined breast cancer treatment, was nominated for Best Podcast - Documentary and Best Indie Podcast – Limited Run in the 29th Annual Webby Awards.
Although lung cancer screening is recommended in the U.S. for certain individuals with a history of smoking, only 18% of eligible individuals in the U.S. get screened.Â
A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.
In 1991, the National Breast Cancer Coalition demanded that the federal government spend $300 million more on breast cancer research. This push resulted in the creation of the Department of Defense Congressionally Directed Medical Research Program, which has broadened to 34 other diseases with an FY24 budget of $1.5 billion.
Breast cancer surgeon Tari A. King was appointed as chief surgical officer for the cancer service line at Winship Cancer Institute of Emory University and Emory Healthcare. Joining Emory on July 14, she will also be the chief of the newly formed Division of Breast Surgery in the Department of Surgery at Emory University School of Medicine and co-director of Winship’s Glenn Family Breast Center.
RWJBarnabas Health and Rutgers Cancer Institute opened a new Breast Health Center in East Brunswick, NJ.Â
Fred Hutch Cancer Center announced 10 recipients of the annual Harold M. Weintraub Graduate Student Award, which recognizes the exceptional achievements of graduate studies in the biological sciences.
To expand access to breast cancer screening for patients across Virginia, UVA Health is rolling out a new mobile mammography coach.
A new analysis by the International Agency for Research on Cancer and collaborators evaluates the latest and future global burden of female breast cancer in about 50 countries worldwide.
Tempus AI Inc. and Stemline Therapeutics Inc. announced a new collaboration. The two companies will leverage Next—Tempus’ AI-enabled care pathway intelligence platform—to help clinicians determine when an ESR1 test may be appropriate.
